Biointron, a leading contract research organization specializing in antibody discovery, expression, and optimization for global biotechnology and pharmaceutical companies, today announced the launch of RushData, a new integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery.
Biointron, a contract research organization specializing in antibody discovery and production services with offices located in Cambridge, Massachusetts, and Piscataway, New Jersey, has released Small-Scale Antibody Expression Packages under the RushMab brand, compressing the wait to as few as 4 days for transfection-grade expression plasmids and 10 days for purified, quality-controlled antibody material.
Biointron launched its Antibody Developability Assessment Services to help drug developers catch potential problems before they turn into expensive failures. The platform combines high-throughput antibody production with a full panel of tests that check whether candidates can be manufactured at scale and remain stable throughout their shelf life, with results delivered in three to five days per assay.
On February 22, 2026, Biointron successfully completed its latest third-party cybersecurity assessment conducted by CyberVadis, achieving an overall score of 923/1000 at the Mature security capability level, which is the highest level in the CyberVadis rating framework.
Biointron, a specialized antibody contract research organization (CRO), has been awarded the 2025 Scientist.com Supplier Performance Recognition Award for outstanding performance in delivering drug discovery research services throughScientist.com’sglobal R&D sourcing platform.Scient
The development of Biointron’s AbDrop, a scalable microfluidics-based platform for high-throughput identification and characterization of plasma cell-derived antibodies, was recently described in a study published in mAbs.
Recognition places Biointron among the top 35% of global performers in sustainability management. Biointron Biological Inc. (Group), has been awarded the EcoVadis Bronze Medal for our commitment to sustainability.
Biointron, a leading contract research organization (CRO) specializing in antibody discovery, optimization, and expression services, is proud to announce more than 2,500 biotech and pharmaceutical customers worldwide. This achievement underscores our trusted role in accelerating antibody research an
Introducing a new High-throughput Fully Humanized Antibody Discovery Platform with Biointron AbDrop & Cyagen HUGO-Ab! This novel approach combines microfluidic technology for single B cell antibody discovery and fully human antibody mice for a safer and more efficient approach for fully human antibody discovery, ready in as quickly as 3 months.
Biointron is proud to share that we have received the 2024 Scientist.com Supplier Performance Recognition Award, for our dedication to providing high-quality drug discovery research services on this industry-renowned R&D sourcing platform.
On July 29, 2024, Biointron achieved a "Mature" score on the Cybervadis assessment. This comprehensive assessment, which evaluated our entire organization and all functions, underscores our commitment to excellence in cybersecurity and risk management.
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
You can also contact us on the Scientist and Science Exchange marketplaces.
